Total submissions: 39
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000167825 | SCV000073571 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000031751 | SCV000154095 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-04-08 | criteria provided, single submitter | literature only | |
Gene |
RCV000152885 | SCV000167412 | benign | not specified | 2014-01-07 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV000131022 | SCV000185950 | benign | Hereditary cancer-predisposing syndrome | 2014-11-19 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Michigan Medical Genetics Laboratories, |
RCV000031751 | SCV000196016 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-11-03 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000152885 | SCV000202304 | likely benign | not specified | 2014-05-01 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000735613 | SCV000219411 | likely benign | Breast and/or ovarian cancer | 2023-03-08 | criteria provided, single submitter | clinical testing | |
Institute for Biomarker Research, |
RCV000167825 | SCV000267847 | likely benign | Hereditary breast ovarian cancer syndrome | 2016-04-25 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000371112 | SCV000383788 | likely benign | Fanconi anemia complementation group D1 | 2018-02-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000031751 | SCV000383789 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-02-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000167825 | SCV000494364 | benign | Hereditary breast ovarian cancer syndrome | 2014-09-29 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000152885 | SCV000538491 | uncertain significance | not specified | 2016-03-28 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: ClinVar: 10 labs classify as LB/Ben; ExAC: 0.1% (94/66682) European chromosomes |
Cancer Genetics and Genomics Laboratory, |
RCV000152885 | SCV000586982 | benign | not specified | 2017-04-19 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000034464 | SCV000602794 | benign | not provided | 2023-10-19 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000131022 | SCV000683983 | likely benign | Hereditary cancer-predisposing syndrome | 2014-11-25 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000031751 | SCV000743349 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-10-09 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000031751 | SCV000744542 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Institute for Biomarker Research, |
RCV000131022 | SCV000747808 | likely benign | Hereditary cancer-predisposing syndrome | 2018-05-23 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000034464 | SCV000805782 | likely benign | not provided | 2017-08-25 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000034464 | SCV001148998 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | BRCA2: BP4 |
Institute for Clinical Genetics, |
RCV000034464 | SCV002010305 | benign | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000167825 | SCV002025857 | likely benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000152885 | SCV002070567 | likely benign | not specified | 2021-09-29 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000131022 | SCV002531958 | benign | Hereditary cancer-predisposing syndrome | 2020-10-19 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000152885 | SCV002551827 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV000031751 | SCV002761833 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2021-09-01 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000031751 | SCV004846043 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Biesecker Lab/Clinical Genomics Section, |
RCV000034464 | SCV000043231 | probably not pathogenic | not provided | 2012-07-13 | no assertion criteria provided | research | Converted during submission to Likely benign. |
Sharing Clinical Reports Project |
RCV000031751 | SCV000054359 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2012-05-01 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031751 | SCV000147403 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Pathway Genomics | RCV000031751 | SCV000207353 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2014-11-06 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000152885 | SCV000592209 | benign | not specified | no assertion criteria provided | clinical testing | The p.Glu2856Ala variant is identified in the literature in 26 out of 7714 proband chromosomes (frequency 0.003) with breast, ovarian and prostate cancers, however it is also identified in 16 out of 5286 control chromosomes (frequency 0.003) (Spitzer 2000, Borg 2010, Soegaard 2008, Edwards 2003, Chenevix-Trench 2006, Evans 2008), and listed in dbSNP database as coming from a "clinical source" (ID#: rs11571747) with an average heterozygosity of 0.002+/-0.031 in various human populations, therefore increasing the likelihood of this variant to be benign. In the UMD database, this variant has been identified in two (out of 23) individuals with breast or ovarian cancers, where a second pathogenic BRCA1 or BRCA2 mutation was also detected, and also found in an breast cancer individual in the homozygous state (Chenevix-Trench 2006), further suggesting the benign nature of this variant. The p.Glu2856 residue is conserved in mammals and computational analyses (PolyPhen2, SIFT, AlignGVGD) provide inconsistent predictions regarding the impact to the protein, leaning more towards deleterious, but this information is not predictive enough to assume pathogenicity. Furthermore, Myriad genetics has reported this variant as a polymorphism increasing the likelihood this variant is benign (personal communication). Based on the above information, this variant is classified as Benign. | |
Diagnostic Laboratory, |
RCV000031751 | SCV000733319 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | no assertion criteria provided | clinical testing | ||
True Health Diagnostics | RCV000131022 | SCV000787955 | likely benign | Hereditary cancer-predisposing syndrome | 2017-08-14 | no assertion criteria provided | clinical testing | |
Foulkes Cancer Genetics LDI, |
RCV000735613 | SCV000863751 | uncertain significance | Breast and/or ovarian cancer | 2001-08-16 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000034464 | SCV001800804 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics Laboratory, |
RCV000152885 | SCV001906421 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000152885 | SCV001951665 | benign | not specified | no assertion criteria provided | clinical testing | ||
BRCAlab, |
RCV000031751 | SCV004243827 | benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |